首页> 外文OA文献 >Macrophage activation syndrome, a rare complication of primary Sjögren’s syndrome: a case report
【2h】

Macrophage activation syndrome, a rare complication of primary Sjögren’s syndrome: a case report

机译:巨噬细胞激活综合征,罕见的小学Sjögren综合症并发症:案例报告

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Abstract Background The association of macrophage activation syndrome and primary Sjögren’s syndrome has been rarely reported in the literature. We report the first observation of this association in Africa, south of the Sahara, and we discuss the diagnosis and therapeutic challenge. Case presentation A 26-year-old Mauritanian and Berber woman was followed for primary Sjögren’s syndrome. After a voluntary cessation of her usual background treatment, she was admitted to our department for an outbreak of her illness. A clinical examination revealed anemic syndrome, peripheral polyarthritis, coughing rales at both pulmonary bases, and fever at 39.5 °C. On biologic examination, there was bicytopenia with anemia at 5.70 g/dl, lymphopenia at 796/mm3, a biological inflammatory syndrome with a sedimentation rate at 137 mm in the first hour, C-reactive protein at 97 mg/l, hyperferritinemia at 1778 mg/l (9 normal value), and hypergammaglobulinemia at 20.7 g/l of polyclonal appearance. The triglycerides were 1.95 g/l (1.4 normal value) and the lactate dehydrogenase level was 491 IU/l (1.5 normal value). Cytological examination of a medullary puncture revealed an image of hemophagocytosis. An infectious screening was negative. Thoracic computed tomography showed non-specific interstitial lung disease. A diagnosis of macrophage activation syndrome complicating primary Sjögren’s syndrome was selected with a probability of 97.2%, according to H-Score. The evolution was favorable under a treatment including etoposide (VP-16). Conclusion Macrophage activation syndrome is a rare entity, rarely reported during primary Sjögren’s syndrome. Its spontaneous evolution is invariably fatal. There is no consensus on therapeutic treatment. Etoposide is a therapeutic option especially in forms refractory to corticosteroid therapy.
机译:摘要背景巨噬细胞激活综合征和原代Sjögren综合征在文献中已经很少报道。我们在撒哈拉州南部的非洲举报了对此协会的首次观察,我们讨论了诊断和治疗挑战。案例介绍一名26岁的毛里塔尼亚和柏柏尔妇女被初级Sjögren的综合症。经过一系列自愿停止她通常的背景治疗,她被我们的部门承认了她的疾病。临床检查揭示了贫血综合征,外周多关节炎,在肺碱的肺碱中咳嗽,在39.5℃下发热。在生物学检查中,患有5.70g / d1的贫血症,796 / mm3的淋巴细胞症,一种生物炎症综合征,在第一个小时内为137 mm,97 mg / L的C反应蛋白为1778年Mg / L(9正常值),高碱性血管血症为20.7g / L多克隆外观。甘油三酯是1.95g / L(1.4正常值),乳酸脱氢酶水平为491 IU / L(1.5正常值)。髓状穿刺的细胞学检查揭示了噬炎的形象。感染性筛查是阴性的。胸廓计算断层扫描显示出非特异性间质性肺病。根据H评分,选择了巨噬细胞激活综合征使原发性Sjögren综合征复杂的巨噬细胞激活综合征的诊断为97.2%。在含有依托泊苷(VP-16)的治疗中,进化是有利的。结论巨噬细胞激活综合征是一种罕见的实体,很少在原发性Sjögren的综合症中报道。它的自发进化是总是致命的。治疗治疗没有达成共识。依托泊苷是一种治疗选择,尤其是形成难治性的皮质类固醇治疗。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号